Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 24, 2024 - Issue 4
Submit an article Journal homepage
163
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2− advanced breast cancer

Juan Honga Department of Pharmacy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, ChinaORCID Iconhttps://orcid.org/0009-0005-2981-5021View further author information
ORCID Icon,
Tujia Chenb Department of Pharmacy, Boai Hospital of Zhongshan, Zhongshan, ChinaView further author information
,
Lihui Ouyangc Department of Pharmacy, The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University, Changsha, ChinaView further author information
,
Ning Dua Department of Pharmacy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, ChinaView further author information
,
Anna Lia Department of Pharmacy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, ChinaView further author information
,
Zhongqi Zhoud School of Pharmacy, Guangdong Medical University, Dongguan, ChinaView further author information
,
HaiLing Zhangd School of Pharmacy, Guangdong Medical University, Dongguan, ChinaView further author information
,
Zhengzheng Xiaa Department of Pharmacy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, ChinaCorrespondence[email protected]
View further author information
&
Jun Menga Department of Pharmacy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, ChinaCorrespondence[email protected]
View further author information
 show all
Pages 559-566 | Received 02 Nov 2023, Accepted 16 Feb 2024, Published online: 20 Mar 2024

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.